Chemo-free regimen touts breast cancer win amid targeted therapy shift
A new study has revealed that an all-targeted treatment regimen could hold potential as an effective frontline therapeutic option for …
Post
-
-
AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
On 17 August, AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig in combination with chemotherapy in first-line metastatic non-small …
-
Study finds metabolic biomarker signature to assist with early HNSCC detection
Head and neck squamous cell carcinoma (HNSCC) is a group of cancers that consists of cancers of the mouth; the …
-
Enrolment opens for Adaptin Bio’s Phase I trial of glioblastoma therapy
Adaptin Bio has opened enrolment for a Phase I clinical trial to assess its Brain Bispecific T cell Engager (BRiTE) therapy, …
-
Polyrizon finalises five site agreements for Nasarix trial
Polyrizon has completed agreements with five sites for its planned clinical trial evaluating Nasarix Allergy Blocker (PL-14) in patients with …
-
The changing landscape of childhood infectious disease in the US
For decades, childhood vaccination has transformed the US infectious disease landscape, reducing diseases such as measles, whooping cough, and polio …
-
AC Immune’s anti-inflammatory drug posts early-stage win
AC Immune’s anti-inflammatory therapy has netted a Phase I, first-in-human win in healthy volunteers, setting a positive precedent as the …
-
Reforms to UK clinical trial sector showing signs of success
Reforms to the UK clinical trial system seem to be working after 82% of studies were found to hit recruitment …
-
UK MHRA grants approval for Scancell’s Phase III study of iSCIB1+
Scancell Holdings has received clinical trial authorisation (CTA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a …
-
Novo Nordisk commences study for reduced Wegovy pill dosing
Novo Nordisk has begun a late-stage clinical trial to evaluate whether lower doses of its oral pill, Wegovy, can still …
-
MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score
MSD and Moderna are vying for the approval of their jointly developed personalised cancer vaccine, intismeran autogene, after the therapy …
-
Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial
Amylyx Pharmaceuticals’ $35m bet on Eiger BioPharmaceuticals’ glucagon-like peptide-1 (GLP-1) receptor antagonist for post-bariatric hypoglycaemia (PBH) has paid off after …
-
Trump expected to nominate Heidi Overton as new FDA commissioner
US President Donald Trump is expected to put forward Heidi Overton as his choice for the next commissioner of the …
-
Abcuro secures $66m to support clinical trial of ulviprubart for IBM
US-based biotechnology company Abcuro has closed a $66m Series D funding round to support its new clinical trial of ulviprubart …
-
Enrolment concludes in Lynch’s Phase II rhPDGF-BB study
Lynch Regenerative Medicine has completed participant enrolment in a Phase II clinical trial assessing the recombinant human pure platelet-derived growth …
